Amisulpride IV Prevention — Competitive Intelligence Brief

Amisulpride IV Prevention (Amisulpride IV Prevention) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine antagonist. Area: Immunology.

phase 3 Dopamine antagonist Dopamine D2/D3 receptors Immunology Small molecule

Target snapshot

Amisulpride IV Prevention (Amisulpride IV Prevention) — Benaroya Research Institute. Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling to prevent or reduce disease progression.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amisulpride IV Prevention TARGET	Amisulpride IV Prevention	Benaroya Research Institute	phase 3	Dopamine antagonist	Dopamine D2/D3 receptors
Aripiprazole or Perphenazine	Aripiprazole or Perphenazine	Johns Hopkins University	marketed	Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine)	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)
Rasagiline mesylate with Requip	Rasagiline mesylate with Requip	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine receptor agonist	MAO-B and dopamine D2/D3 receptors
omeprazole+domperidone SR	omeprazole+domperidone SR	Belarusian Medical Academy of Post-Graduate Education	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (omeprazole); dopamine D2/D3 receptors (domperidone)
Lamotrigine + Aripiprazole	Lamotrigine + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Anticonvulsant/mood stabilizer + atypical antipsychotic combination	Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole)
Lithium or Valproate with Aripiprazole	Lithium or Valproate with Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic combined with mood stabilizers	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); inositol monophosphatase, GSK-3 (lithium); histone deacetylase (valproate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine antagonist class)

1. Benaroya Research Institute · 1 drug in this class
2. Dr. Reddy's Laboratories Limited · 1 drug in this class
3. Hospital de Clinicas de Porto Alegre · 1 drug in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
5. University Hospital, Bordeaux · 1 drug in this class